Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.55 |
| ▸ | EGLN1 | Q9GZT9 | 4/20 | 0.53 |
| ▸ | MET | P08581 | 4/20 | 0.51 |
| ▸ | IKBKB | O14920 | 2/20 | 0.51 |
| ▸ | ATR | Q13535 | 1/20 | 0.49 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | CSF1R | P07333 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12616233 | 1.00 | HRH3 (0.55) | HRH3EGLN1METIKBKBATR | |
| SCHEMBL5908973 | 0.86 | HRH3 (0.56) | HRH3EGLN1METIKBKBATR | |
| SCHEMBL1794728 | 0.83 | HRH3 (0.61) | HRH3METIKBKBKCNH2CSF1R | |
| SCHEMBL1794727 | 0.83 | HRH3 (0.61) | HRH3METIKBKBKCNH2CSF1R | |
| SCHEMBL1796418 | 0.80 | MAPT (0.51) | HRH3EGLN1METIKBKB | |
| SCHEMBL12616218 | 0.80 | MAPT (0.51) | HRH3EGLN1METIKBKB | |
| SCHEMBL3193241 | 0.79 | HRH3 (0.55) | HRH3EGLN1METIKBKBATR | |
| SCHEMBL1835474 | 0.79 | HRH3 (0.60) | HRH3METIKBKBKCNH2 | |
| SCHEMBL2745180 | 0.79 | HRH3 (0.64) | HRH3METKCNH2CSF1R | |
| SCHEMBL1799107 | 0.79 | HRH3 (0.60) | HRH3METIKBKBKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1861360-B1 | PYRROLIDINE DERIVATIVES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2009-12-02 | — | — | EP | claimed |
| US-20080207732-A1 | Pyrrolidine Derivatives as Histamine H3 Receptor Antagonists | ELI LILLY AND COMPANY | 2008-08-28 | — | — | US | claimed |
| EP-1861360-A1 | PYRROLIDINE DERIVATIVES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2007-12-05 | — | — | EP | claimed |
| WO-2006101808-A1 | PYRROLIDINE DERIVATIVES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2006-09-28 | — | — | WO | claimed |
| US-7951826-B2 | Obesity; cognition activators; narcolepsy | ELI LILLY AND COMPANY (US) | 2011-05-31 | — | — | US | disclosed |
| US-7951826-B2 | Obesity; cognition activators; narcolepsy | ELI LILLY AND COMPANY (US) | 2011-05-31 | — | — | US | disclosed |
| US-7951826-B2 | Obesity; cognition activators; narcolepsy | ELI LILLY AND COMPANY (US) | 2011-05-31 | — | — | US | disclosed |
| EP-1861360-B1 | PYRROLIDINE DERIVATIVES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20080207732-A1 | Pyrrolidine Derivatives as Histamine H3 Receptor Antagonists | ELI LILLY AND COMPANY | 2008-08-28 | — | — | US | disclosed |
| US-20080207732-A1 | Pyrrolidine Derivatives as Histamine H3 Receptor Antagonists | ELI LILLY AND COMPANY | 2008-08-28 | — | — | US | disclosed |
| US-20080207732-A1 | Pyrrolidine Derivatives as Histamine H3 Receptor Antagonists | ELI LILLY AND COMPANY | 2008-08-28 | — | — | US | disclosed |
| EP-1861360-A1 | PYRROLIDINE DERIVATIVES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006101808-A1 | PYRROLIDINE DERIVATIVES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207732-A1 | Pyrrolidine Derivatives as Histamine H3 Receptor Antagonists | HRH3, HCRTR1, HRH4 | HRH3 1/4885EGLN1 584/4885MET 1108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.